Concomitant chronic myeloid leukemia and monoclonal B cell lymphocytosis – a very rare condition

Duarte, Sara; Pereira, Sónia Campelo; Rodrigues, Élio; Pereira, Amélia

doi:10.1016/j.bjhh.2017.02.004

Cited by 1 publication

(2 citation statements)

References 11 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally accepted that myeloid and lymphoid neoplasms emerge and progress independently. However, there are difficulties when trying to identify a biclonal origin of the two lymphoid and myeloid clones, evidence of which is still lacking (4).…”

Section: Discussionmentioning

confidence: 99%

“…CLL/SLL is a disorder of morphologically mature but immunologically incompetent B lymphocytes. It is defined as >5x10 3 /µl circulating B lymphocytes with a specific phenotype expressing CD19, CD5, CD23, CD43 and CD200, and a weak expression of CD20, CD79b and surface immunoglobulin (4). Key pathways promoting CLL cell proliferation and survival are activation of B-cell receptor and nuclear factor-κB pathways (5).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature

et al. 2018

View full text Add to dashboard Cite

Patients with a Philadelphia chromosome-negative myeloproliferative neoplasm may develop a lymphoproliferative disorder; however, the clinical and molecular determinants and the chronological onset of the two events remain unknown. We herein report the case of a 64-year-old man with concomitant diagnosis of high-risk essential thrombocythemia with evidence of a thrombotic event and high-count monoclonal B-cell lymphocytosis (high-count MBL). The patient harbored a JAK2V617F mutation and one of the most common genetic alterations found in chronic lymphocytic leukemia (CLL) (del 13q), which may represent a sign of disease progression. He was initiated on cytoreductive therapy with hydroxyurea 500 mg 3 times per week and hypocoagulation treatment, and is currently under regular surveillance of MBL without CLL criteria.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%